| Business Summary | | Incyte
Genomics,
Inc.
provides
genomics
technologies
and
products
to
the
biotechnology
and
pharmaceutical
industries
and
research
and
academic
institutions.
The
Company's
products
and
services
include
databases,
bioreagents,
custom
sequencing,
gene
expression,
SNP
discovery
and
other
services.
The
Company's
portfolio
of
products
and
services
includes
LifeSeq
Gold
human
gene
sequence
database;
ZooSeq
animal
model
gene
sequence
database;
LifeExpress
gene
and
protein
expression
database;
a
Genetics
program
that
identifies
common
DNA
sequence
variants
between
individuals;
microarray-based
expression
services;
bioreagents;
and
custom
sequencing
and
other
custom
services. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | INCY
designs,
develops
and
markets
genomic
information
based
tools
including
database
products,
genomic
data
management
software
tools,
microarray-based
gene
expression
services
and
genomic
reagents
and
related
services.
For
the
six
months
ended
6/30/01,
revenues
rose
24%
to
$107.2
million.
Net
loss
before
acct.
change
and
extraordinary
item
rose
68%
to
$24.9
million.
Results
reflect
higher
partnership
program
and
custom
genomics
sales.
Higher
loss
reflects
higher
R&D
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Randal Scott, Ph.D., 43 Chairman | $368K | $3.8M | Roy Whitfield, 47 CEO | 595K | 1.8M | John Vuko, 50 CFO | 382K | -- | Michael Lack, 49 COO | 456K | -- | E. Lee Bendekgey, 43 Exec.
VP, Gen. Counsel, Sec. | 375K | 2.4M | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|